Find Funding Opportunities

The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Child Health and Human Development (NICHD), the National Institute of Mental Health (NIMH), the International Rett Syndrome Association (IRSA) and the Rett Syndrome Research Foundation (RSRF) invite research grant applications aimed at understanding and/or treating Rett Syndrome (RTT). The recent demonstration that mutations in the MECP2 gene cause most cases of RTT has created new opportunities for both basic and clinical research. Included within the scope of this funding opportunity announcement (FOA) with set-aside funds are developmental, neuroanatomical, molecular genetic, and pathophysiological research, therapy development projects and clinical studies. Studies of the role of MeCP2 in basic biological processes or in the etiology of other neurological or neurobehavioral disorders are also appropriate. - This funding opportunity announcement (FOA) will utilize the NIH Small Grant (R03) award mechanism, but runs in parallel with two FOAs of identical scientific scope that utilize the traditional research project grant (R01) [PAS-05-024] and exploratory/developmental research grant (R21) [PAS-06-274] mechanisms, respectively.- The participating organizations intend to commit a total of $2,600,000 to this FOA for payment of applications responsive to this announcement and two parallel FOAs that utilize the R01 and R21 mechanisms. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -Eligible organizations include For-profit organizations; Non-profit organizations; Public or private institutions, such as universities, colleges, hospitals, and laboratories; Eligible agencies of the Federal government; Units of State government; Units of local government ; Foreign Institutions; Domestic Institutions; Faith-based or community-based organizations; and units of state or local tribal governments. -Eligible Project Directors/Principal Investigators (PD/PIs): Any individual with the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support -An R03 is not renewable. -Applicants may submit more than one application, provided each is scientifically distinct.

The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Child Health and Human Development (NICHD), the National Institute of Mental Health (NIMH), the International Rett Syndrome Association (IRSA) and the Rett Syndrome Research Foundation (RSRF) invite research grant applications aimed at understanding and/or treating Rett Syndrome (RTT). The recent demonstration that mutations in the MECP2 gene cause most cases of RTT has created new opportunities for both basic and clinical research. Included within the scope of this funding opportunity announcement (FOA) with set-aside funds are developmental, neuroanatomical, molecular genetic, and pathophysiological research, therapy development projects and clinical studies. Studies of the role of MeCP2 in basic biological processes or in the etiology of other neurological or neurobehavioral disorders are also appropriate.

The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Drug Abuse (NIDA) and the National Institute of Mental Health (NIMH) invite research grant applications aimed at developing non-human lentiviral in vivo model systems for study of the neurologic complications of AIDS, with or without a history of drug use. Recent advances in the development of the SIV model system highlight the power of animal model systems for study of the mechanisms underlying the pathology associated with lentiviral infection in the nervous system. These models will be key for developing therapeutic approaches for the treatment of patients suffering from NeuroAIDS and for understanding the basic biology of infection with HIV/AIDS.

The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Drug Abuse (NIDA) and the National Institute of Mental Health (NIMH) invite research grant applications aimed at developing non-human lentiviral in vivo model systems for study of the neurologic complications of AIDS, with or without a history of drug use. Recent advances in the development of the SIV model system highlight the power of animal model systems for study of the mechanisms underlying the pathology associated with lentiviral infection in the nervous system. These models will be key for developing therapeutic approaches for the treatment of patients suffering from NeuroAIDS and for understanding the basic biology of infection with HIV/AIDS. -This funding opportunity will use the NIH Exploratory/Developmental Grant (R21) award mechanism, but will be run in parallel with two FOAs of identical scientific scope that utilize the traditional research project grant (R01) [PAS-05-078] and small research grant (R03) [PAS-06-275] mechanisms, respectively. -The participating organizations intend to commit a total of $2,150,000 to this FOA for payment of applications responsive to this announcement and two parallel announcements that use the R01 and R03 mechanisms. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -Eligible organizations: For-profit organizations; Non-profit organizations; Public or private institutions, such as universities, colleges, hospitals, and laboratories; Eligible agencies of the Federal government; Units of State government; Units of local government ; Foreign Institutions; Domestic Institutions; Faith-based or community-based organizations; and units of state or local tribal governments. -Eligible Project Directors/Principal Investigators (PD/PIs): Any individual with the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. -An R21 is not renewable.. -Applicants may submit more than one application, provided they are scientifically distinct

As summarized in the 2003 National Sleep Disorders Research Plan (http://www.nhlbi.nih.gov/health/prof/sleep/res_plan/index.html), multiple scientific areas in sleep and sleep disorders need additional research. In addition, therapy for a number of sleep disorders remains suboptimal, and the research workforce addressing sleep science is insufficient. The NHLBI, National Center on Sleep Disorders Research, and co-sponsoring member Institutes and Centers of the Trans-NIH Sleep Research Coordinating Committee therefore invite submission of grant applications proposing research to advance biomedical knowledge related to sleep or sleep disorders, improve understanding of the neurobiology or functions of sleep over the life-span, enhance timely diagnosis and effective treatment for individuals affected by sleep-related disorders, or implement and evaluate innovative community-based public health education and intervention programs.

-The goal of this International Neuroscience Fellowship Program is to provide a unique opportunity to qualified foreign neuroscientists, at junior or mid-career level, to receive one to two years of research training in the United States (U.S.). -The number of awards that will be funded under this program announcement is contingent upon the quality of the applications received, the availability of funds, and the program priorities of the participating NIH institutes. -This program announcement uses the international research fellowship (F05) award mechanism. -Eligible U.S. sponsoring organizations include for-profit or non-profit organizations; public or private institutions, such as universities, colleges, hospitals, and laboratories; and eligible agencies of the U.S. Federal government. -Eligible individual applicants include non-immigrant foreign scientists who are currently residing outside the U.S.The applicant must have a doctoral or equivalent degree, an endorsement from their home institution, and a guaranteed appointment in an institution in their home country upon completion of the fellowship. Applicants must have a sponsor in the U.S. who is affiliated with an eligible U.S. organization and must be proficient in English. Preference will be given to applicants from low- to middle-income countries. -Applicants must use the most recent version of the PHS 416-1 form (Rev. 10/05) http://grants.nih.gov/grants/funding/416/phs416.htm. Since the PHS 416-1 form is used for several different types of fellowship applications, not all statements in the PHS 416-1 form are applicable to the International Neuroscience Fellowship Program. -An individual applicant may not have more than one competing NIH fellowship application pending review concurrently.

The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Drug Abuse (NIDA), the National Institute on Deafness and Other Communication Disorders (NIDCD), the National Institute on Aging (NIA), the National Eye Institute (NEI), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the National Cancer Institute (NCI), and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications for studies on the cellular and molecular signaling between the local environment within organisms and stem and progenitor cells that are either introduced as transplants or are normally resident within host tissues and organs. The objective of this initiative is to promote a thorough exploration and characterization of the bi-directional communication between multipotent cells and the three-dimensional local milieu or niche that they encounter in vivo under normal and compromised states, such as with aging or following injury, disease or drug exposure. -This funding opportunity announcement (FOA) will utilize the NIH Small Grant (R03) award mechanism, but runs in parallel with two program announcements of identical scientific scope that utilize the traditional research project grant (R01) [http://grants.nih.gov/grants/guide/pa-files/PAS-05-092.html] and exploratory/developmental research grant (R21) [PAS-06-208] mechanisms, respectively. -The participating organizations intend to commit a total of $2,700,000 to this FOA for payment of applications responsive to this announcement and two parallel announcements that use the R01 and R21 mechanisms. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -Project Period and Award Levels: A total project period of up to two years and a budget for direct costs of up to two $25,000 modules or $50,000 per year may be requested. -Eligible organizations include: For-profit organizations; Non-profit organizations; Public or private institutions, such as universities, colleges, hospitals, and laboratories; Eligible agencies of the Federal government; Units of State government; Units of local government ; Foreign Institutions; Domestic Institutions; Faith-based or community-based organizations; and units of state or local tribal governments. -Eligible Project Directors/Principal Investigators (PD/PIs): Any individual with the skills, knowledge and resources necessary to carry out the proposed research, is invited to work with his/her institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. -An R03 is not renewable. 

The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Drug Abuse (NIDA), the National Institute on Deafness and Other Communication Disorders (NIDCD), the National Institute on Aging (NIA), the National Eye Institute (NEI), the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the National Cancer Institute (NCI), and National Institute on Alcohol Abuse and Alcoholism (NIAAA) invite applications for studies on the cellular and molecular signaling between the local environment within organisms and stem and progenitor cells that are either introduced as transplants or are normally resident within host tissues and organs. The objective of this initiative is to promote a thorough exploration and characterization of the bi-directional communication between multipotent cells and the three-dimensional local milieu or niche that they encounter in vivo under normal and compromised states, such as with aging or following injury, disease or drug exposure. -This funding opportunity announcement (FOA) will utilize National Institutes of Health (NIH) exploratory/developmental (R21) award mechanism, but runs in parallel with two FOAs of identical scientific scope that will utilize the traditional research project grant (R01) [http://grants.nih.gov/grants/guide/pa-files/PAS-05-092.html] and small research grant (R03) [PAS-06-207] mechanisms, respectively. -The participating organizations intend to commit a total of $2,700,000 to this FOA for payment of applications responsive to this announcement and two parallel announcements that use the R01 and R03 mechanisms. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -Project Period and Award Levels: The applicant may request a project period of up to two years with a combined budget for direct costs of up to $275,000 for the two-year period. -Eligible organizations: For profit organizations; Non-profit organizations; Public or private institutions, such as universities, colleges, hospitals and laboratories; Units of State government; Units of local government; Eligible institutions of the Federal government; Domestic institutions; Foreign institutions; Faith-based or community-based organizations; Units of State Tribal government; and Units of Local Tribal government. -Eligible Project Directors/Principal Investigators (PD/PIs): Any individual with the skills, knowledge and resources necessary to carry out the proposed research, is invited to work with his/her institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. -Applicants may submit more than one application, provided each application is scientifically distinct. -An R21 is not renewable. 

-This PAR is for projects from individual-investigators or small groups to collaborate with the recently-formed NIH Roadmap for Medical Research National Centers for Biomedical Computing (NCBCs). For a description of the NCBCs see http://www.bisti.nih.gov/ncbc/index.cfm. -This announcement uses the R21 mechanism, and is intended to support exploratory biomedical informatics and computational biology researchapplications should be innovative, with high risk/high impact in new areas that are lacking preliminary data or development.Applications for R21 awards should describe projects distinct from those supported through the traditional R01 mechanism.In the latter case, investigators should consult the parallel announcement PAR-05-063 "Collaborations with National Centers for Biomedical Computing".For example, long-term projects, or projects designed to increase knowledge in a well-established area will not be considered for R21 awards. -The intention of the collaborating projects is to engage researchers across the nation in building an excellent biomedical computing environment, using the computational tools and biological and behavioral application drivers of the funded NCBCs as foundation stones. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary.The applicant may request a project period of up to two years with a combined budget for direct costs of up to $275,000 for the two year period. The request should be tailored to the needs of the project. Normally, no more than $200,000 may be requested in a single year. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received. -Successful applications will be funded by the participating ICs. -Eligible organizations include: for-profit or non-profit organizations; public or private institutions, such as universities, colleges, hospitals, and laboratories; units of state and local governments; eligible agencies of the Federal government; domestic or foreign institutions/organizations. -Eligible PIs include any individual with the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. -There is no limit to the number of scientifically different applications that each applicant may submit. However, each application must include a letter of support from the PI of the NCBC with whom the collaboration is proposed. -Application forms are available at http://grants.nih.gov/grants/funding/phs398/phs398.html.

The goal of this funding opportunity announcement (FOA)is to promote the identification of susceptibility genes for complex neurological and neurobehavioral disorders. - This funding opportunityannouncement (FOA) will utilize the R21 mechanism, but runs in parallel with a program announcement of identical scientific scope that utilizes the traditional research project grant (R01) [PAS-03-092] award mechanism. -The participating Institutes intend to commit a combined total of approximately $3,000,000 (total costs) per year to this FOA and a second FOA of identical scientific scope that utilizes the R01 mechanism. These funds are in addition to funds available for applications sent in response to these announcements that score within the paylines of the participating NIH Institutes. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -Project Period and Award Levels: The total project period for an application submitted in response to this funding opportunity may not exceed two years. Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year. -Eligible organizations: For profit organizations; Non-profit organizations; Public or private institutions, such as universities, colleges, hospitals and laboratories; Units of State government; Units of local government; Eligible institutions of the Federal government; Domestic institutions; Foreign institutions; Faith-based or community-based organizations; Units of State Tribal government; and Units of Local Tribal government. -Eligible Project Directors/Principal Investigators (PD/PIs): Any individual with the skills, knowledge and resources necessary to carry out the proposed research, is invited to work with his/her institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. -Applicants may submit more than one application, provided each application is scientifically distinct. -An R21 is not renewable.